-
Kremlin denies three-way US-Ukraine-Russia talks in preparation
-
Williamson says 'series by series' call on New Zealand Test future
-
Taiwan police rule out 'terrorism' in metro stabbing
-
Australia falls silent, lights candles for Bondi Beach shooting victims
-
DR Congo's amputees bear scars of years of conflict
-
Venison butts beef off menus at UK venues
-
Cummins, Lyon doubts for Melbourne after 'hugely satsfying' Ashes
-
'It sucks': Stokes vows England will bounce back after losing Ashes
-
Australia probes security services after Bondi Beach attack
-
West Indies need 462 to win after Conway's historic century
-
Thai border clashes displace over half a million in Cambodia
-
Australia beat England by 82 runs to win third Test and retain Ashes
-
China's rare earths El Dorado gives strategic edge
-
Japan footballer 'King Kazu' to play on at the age of 58
-
New Zealand's Conway joins elite club with century, double ton in same Test
-
Australian PM orders police, intelligence review after Bondi attack
-
Durant shines as Rockets avenge Nuggets loss
-
Pressure on Morocco to deliver as Africa Cup of Nations kicks off
-
Australia remove Smith as England still need 126 to keep Ashes alive
-
Myanmar mystics divine future after ill-augured election
-
From the Andes to Darfur: Colombians lured to Sudan's killing fields
-
Eagles win division as Commanders clash descends into brawl
-
US again seizes oil tanker off coast of Venezuela
-
New Zealand 35-0, lead by 190, after racing through West Indies tail
-
West Indies 420 all out to trail New Zealand by 155
-
Arteta tells leaders Arsenal to 'learn' while winning
-
Honour to match idol Ronaldo's Real Madrid calendar year goal record: Mbappe
-
Dupont helps Toulouse bounce back in Top 14 after turbulent week
-
Mbappe matches Ronaldo record as Real Madrid beat Sevilla
-
Gyokeres ends drought to gift Arsenal top spot for Christmas
-
Arsenal stay top despite Man City win, Liverpool beat nine-man Spurs
-
US intercepts oil tanker off coast of Venezuela
-
PSG cruise past fifth-tier Fontenay in French Cup
-
Isak injury leaves Slot counting cost of Liverpool win at Spurs
-
Juve beat Roma to close in on Serie A leaders Inter
-
US intercepts oil tanker off coast of Venezuela: US media
-
Haaland sends Man City top, Liverpool beat nine-man Spurs
-
Epstein victims, lawmakers criticize partial release and redactions
-
Leverkusen beat Leipzig to move third in Bundesliga
-
Lakers guard Smart fined $35,000 for swearing at refs
-
Liverpool sink nine-man Spurs but Isak limps off after rare goal
-
Guardiola urges Man City to 'improve' after dispatching West Ham
-
Syria monitor says US strikes killed at least five IS members
-
Australia stops in silence for Bondi Beach shooting victims
-
Olympic champion Joseph helps Perpignan to first Top 14 win despite red card
-
Zelensky says US mooted direct Ukraine-Russia talks on ending war
-
Wheelchair user flies into space, a first
-
Brazil's Lula, Argentina's Milei clash over Venezuela at Mercosur summit
-
Haaland sends Man City top, Chelsea fightback frustrates Newcastle
-
Thailand on top at SEA Games clouded by border conflict
Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2025
DORADO, PUERTO RICO / ACCESS Newswire / September 15, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the three and nine months ended July 31, 2025 were approximately $2.0 million and $6.9, million, respectively. Revenues for the three and nine months ended July 31, 2024 were approximately $2.4 million and $7.2 million, respectively. Net loss for the three and nine months ended July 31, 2025 was approximately $0.2 million and $0.1 million, respectively, an earnings increase of approximately $0.1 million and $0.7 million when compared to the same periods last year, respectively.
"Over the past quarters, we have taken decisive steps to streamline our cost structure, prioritize core business segments, and exit less profitable areas. We believe these efforts have positioned the Company to capitalize on new opportunities with greater agility and focus. We are encouraged by the momentum building across our operations and are preparing for the immediate commencement of several significant projects. The Company remains committed to delivering long-term value to shareholders through disciplined execution," stated Mr. Sanchez Chief Executive Officer of the Company.
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2024, and in its other filings with the Securities and Exchange Commission, which filings are available at www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709
SOURCE: Pharma-Bio Serv Inc.
View the original press release on ACCESS Newswire
Y.Aukaiv--AMWN